Oration from Leadership

“As a member of Grandpharma, we have a dual mission: one is to inherit the spirit of dedication from the red pharmaceutical company, the other is to continuously pursue innovation and excellency.

Our vision is to become a pharmaceutical company respected by Chinese patients and doctors and make a positive contribution to society. It inspires us to expand our enterprise and strengthen ourselves by focusing on R&D and providing quality and affordable products by which patients can be cured. Meanwhile, it is important to promote our products in a way that doctors respect while meeting their treatment needs.

A group of dreamers with a consistent spirit of innovation and perseverance are good at solving complex problems. When the opportunity comes, we will lead the company to a rapid development.”

                                                                             -------SHI XIAOFENG, Chairman and President of Grandpharma(China) Co., Ltd.        

Brief Introduction

Grandpharma (China) Co., Ltd. was founded in 1939, formerly a pharmaceutical factory located in one of the Liberated Zones—Taihang Mountain, and we have made great contributions to China’s liberation cause. Over more than 80 years of development, Grandpharma has always adhered to the spirit of "dare to lead and happy to share" and taking " providing quality products with sincere and honesty " as our business philosophy, as we have constantly enhanced our core business advantages and been committed to becoming a pharmaceutical company respected by doctors and patients.

In 2002, Grandpharma joined China Grand Enterprises and in 2008, we became the core enterprise of China Grand Pharmaceutical and Healthcare Holdings Limited, which is listed in Hong Kong Stock Exchange (HK00512). At present, the company is a modern and comprehensive pharmaceutical enterprise which has more than 20 member enterprises. We have three strategic business areas including various kinds of preparations, medical devices and chemical raw materials, meanwhile, areas of emergency cardiocerebrovascular care, interventional therapy, aspiration, otorhinolaryngology, rare diseases, and biological health are also what we focus on.

In recent years, Grandpharma is strategically taking a comprehensive transformation under the guidance of innovation ideas, and expanding its market with distributing global layout simultaneously. Having acquired a series of innovative pharmaceutical products with broad market prospects from the United States, Australia, Germany, Canada and other pharmaceutical powers, Grandpharma establishes a deep cooperative R & D relation with the world's leading pharmaceutical enterprises, universities and scientific research institutions. In 2018, Grandpharma and CDH Investments invested nearly 10 billion RMB to acquire a 100% equity stake of an Australian company Sirtex. The exclusive anti-liver cancer treatment product from Sirtex called "SIR-Spheres Y-90 resin microspheres" is expected to arrive in China soon and will bring the good news for thousands of Chinese liver cancer patients.

As the annual report of the listed company shows, the compound growth rate of sales revenue and net profit of Grandpharma has reached 27% and 40% respectively in the past three years, which is much higher than that of the average listed pharmaceutical companies. In 2019, Grandpharma ranked 28th in the overall strength of China's chemical and pharmaceutical industry. In addition, Grandpharma is also a Production Enterprise of First-Aid Drugs for National War Preparedness and Reserve, National Base for Basic Drugs, National Small-Variety Medicine Production Base and National Enterprise Technology Center. Plus, it is also a National Evaluation Enterprise of the "Informatization and Industrialization Management System", National Demonstration Enterprise for Integrated Development of Manufacturing Industry and Internet, National Intellectual Property Demonstration Enterprise, and Hubei GMP Training Base.

In the future, Grandpharma will strive to grow into a first-class enterprise with worldwide competitive advantages by focusing on innovative research and development, building a global compliance system, and at the same time, enhancing the overall competitiveness of our enterprises, building high-end talent pools, and achieving a balanced development of shareholders, employees and social benefits. With a foresighted, goal-oriented and multi-line core strategic support, Grandpharma will unleash the company’s market value to start up a high-quality second business and achieve the ambitious medium-term development plan in a more wholistic and comprehensive manner —— the goal of reaching 30 billion sales scale.

History

  • 2020

    In 2020, Grandpharma obtained the exclusive production (including technology transfer) and commercialization rights of CBT001, a global innovative ophthalmic product developed by Cloudbreak Therapeutics.

  • 2020

    In 2020, Grandpharma invested in Chongqing Anti New Biotechnology Co., Ltd. and obtained pharmaceutical technology and related global intellectual property rights of APAD, a pioneer medicine for sepsis.

  • 2020

    In 2020, Grandpharma acquired the controlling stake in a Nasdaq-listed company OncoSec and obtained the exclusive rights to develop and commercialize TAVO, its world-first tumor immunotherapy product, in China and other 38 Asian countries.

  • 2020

    In 2020, Grandpharma invested in Biotechnology Co., Ltd. to acquire the rights to develop and commercialize BRM421, the world's first dry eye treatment, and related technologies in mainland China, Hong Kong and Macao (Greater China).

  • 2019

    In 2019, Grandpharma acquired global development and commercialization rights of sepsis drugs from Australian National University of Science (ANU), with whom Grandpharma will cooperate and development of anti-sepsis drugs.

  • 2019

    In 2019, Grandpharma signed an exclusive licensing and cooperative research and development agreement with the Griffith University to acquire the global rights to develop and commercialize the world's pioneer product and technology for treating parainfluenza.

  • 2019

    In 2019, invested in India's pharmaceutical giant Glenmarks global new compound product RyaltrisTMNasal Spray and acquired the market rights and interests in China.

  • 2018

    2018, Grandpharma and CDH Investments invested nearly 10 billion RMB to acquire a 100% equity stake of an Australian listed company Sirtex. The exclusive anti-liver cancer treatment product from Sirtex called "SIR-Spheres Y-90 resin microspheres" indicates that Grandpharma has entered the field of interventional oncology....

  • 2018

    In 2018, the acquisition of Shanghai Xudong Haipu Pharmaceutical Co., Ltd. was completed.

  • 2017

    In 2017, Grandpharma had a joint venture with Conavi, a Canadian company whose core products are endovascular and intracardiac imaging diagnostic equipment. The joint venture indicates that we have entered the field of cardiovascular diagnosis and realized the combination of cardiovascular diagnosis and treatment....

  • 2016

    Acquired equity interests of Xi`an Beilin Co., Ltd.

  • 2015

    Acquired equity interests of Beijing Jiuhe Co., Ltd.

  • 2013

    Formed a joint venture company with Huangshi Feiyun Co., Ltd. July 2013, acquired equity interests of Beijing Huajin Co., Ltd. At the end of 2010, completed relocation of the whole company.

  • 2012

    Formation of Hubei Grand Bio-technology Limited. November 2012, acquired Hubei Wellness Pharmaceutical Company Limited.

  • 2011

    Change of name into Grand Pharma (China) Co., Ltd., and completed brand integration of Grand Pharma.

  • 2010

    Acquired Hubei Grand Everyday Bright Eyes Company Ltd., June 2010, Took over Hubei Grand Fuchi Pharmaceutical and Chemical Co., Ltd.

  • 2008

    Altered equity structure and indirectly listed in HK Stock Market.Later, completed the acquisition with Wuhan Grand Hoyo Co., Ltd.

  • 2002

    Joined China Grand Enterprises,then renamed Wuhan Grand Pharmaceutical Co., Ltd.

  • 1960

    The exclusive product Dimercaprol saved 61 Proletarian lives.

  • 1953

    Named Wuhan Pharmaceutical Factory.

  • 1939

    Founded in 1939 in the Liberated ZoneTaihang Mountain

  • 2020
  • 2020
  • 2020
  • 2020
  • 2019
  • 2019
  • 2019
  • 2018
  • 2018
  • 2017
  • 2016
  • 2015
  • 2013
  • 2012
  • 2011
  • 2010
  • 2008
  • 2002
  • 1960
  • 1953
  • 1939

Corporate Culture

Our vision:

To benefit both patients and doctors and contribute to a better society.

Our philosophy:

Providing quality products with sincerity and integrity.

Our spirt:

Dare to lead and happy to share.

Our slogan:

Grand journey for a healthier world.

Subsidiaries

API

Wuhan Wuyao Pharmaceutical Co., Ltd.

Wuhan Wuyao Pharmaceutical Co., Ltd.

Founded in July 2002, Wuhan Wuyao Pharmaceutical Co., Ltd. is a subsidiary invested by Grandpharma (China) Co., Ltd.

Main products: More than 40 kinds of API or (medicine) intermediates such as Analgin (Metamizole Sodium Tablets), Metronidazole Buccal Tablets, Chloramphenicol Eye Drops, Enoxacin Tablets, Pirenoxine Sodium etc.

Official Website:www.wyzy.cn

Address:No.18, Wangfen Road, Fuchi Town, Yangxin County, Huangshi, Hubei Province, China

Close
Hubei Grand Fuchi Pharmaceutical & Chemicals Co., Ltd.

Hubei Grand Fuchi Pharmaceutical & Chemicals Co., Ltd.

Hubei Grand Fuchi Pharmaceutical & Chemicals Co., Ltd. was established in September 1997, and joined Grand Pharma (China) Co., Ltd in 2010.

Main products: Dimethyl Sulfate, Nitromethane, O-methylisourea Salt and its derivatives, Imine Complex, Imido Complex, Industrial Sulfuric Acid, Calcium Superphosphate, Omplex Fertilizer, Biological Organic Fertilizer.

Official Website:www.fuchigroup.com

Address:No.12, Wangfen Road, Fuchi Town, Yangxin County, Huangshi, Hubei Province, China

Close
Fuchi Pharmaceutical Co., Ltd.

Fuchi Pharmaceutical Co., Ltd.

Grandpharma Fuchi Industrial Garden is a combination of four holding subsidiaries of Grandpharma (China) Co., Ltd. It is a comprehensive chemical enterprise industrial garden that integrates agrochemicals, fine chemicals and chemical pharmaceuticals.

Official Website:No

Address:No.12, Wangfen Road, Fuchi Town, Yangxin County, Huangshi, Hubei Province, China

Close

Biotech

Hubei Grand Biotechnology Co., Ltd.

Hubei Grand Biotechnology Co., Ltd.

Hubei Grand Biotechnology Co., Ltd. was established in September 2012 as a subsidiary of Grandpharma (China) Co., Ltd.

Main product: L-cysteine

Official Website:No

Address:No.12, Wangfen Road, Fuchi Town, Yangxin County, Huangshi, Hubei Province, China

Close
Wuhan Grand Hoyo Co., Ltd.

Wuhan Grand Hoyo Co., Ltd.

Wuhan Grand Hoyo Co., Ltd. was founded in April 2000, and joined Grandpharma (China) Co., Ltd in 2008.

Main products: Amino Acid Drugs, Food Additives, and Fined Chemicals.

Official Website:www.grandhoyo.com/

Address:Room 601, B Block, Dingye Building, International Business Center Phase III, Optics Valley Avenue, Wuhan, Hubei Province, China

Close
Wuhan Kernel Bio-tech Co., Ltd.

Wuhan Kernel Bio-tech Co., Ltd.

Wuhan Kernel Bio-tech Co., Ltd. was established in April 1999 and has been acquired by Grandpharma (China) Co., Ltd in 2011.

It is mainly engaged in R&D, manufacturing, marketing and technical service in biological fields such as bio-pesticides, microbial-fertilizer, microbial green products and biological feed additives etc.

Official Website:www.biokn.com/

Address:No.17, Guannanyuan Road, Guannan Science and Technology Industrial Park, East Lake High-tech Development Zone, Wuhan, Hubei Province, China

Close
Grand Life Science and Technology Co., Ltd.

Grand Life Science and Technology Co., Ltd.

Grand Life Science and Technology Co., Ltd was founded in September 2002 and joined Grandpharma in 2010.

Main product: Taurine.

Official Website:http://www.chinataurine.net/

Address:Address: No.12, Wangfen Road, Fuchi Town, Yangxin County, Huangshi, Hubei Province, China.

Close

Formulations

Grandpharma (China) Co., Ltd FDF Branch Factory

Grandpharma (China) Co., Ltd FDF Branch Factory

Grandpharma (China) Co., Ltd FDF Branch Factory is a branch plant established in August 2013 by Grandpharma (China) Co., Ltd.

Main products: Tirofiban Hydrochloride Sodium Chloride Injection (Xin Weining), Adrenergic Injection, Metoprolol Tartrate Tablets, Trimetazidine Hydrochloride Tablets, Metronidazole Buccal Tablets, Compound Liquorice Tablets.

Official Website:No

Address:No.11, Huanhu Middle Road, Dongxihu Dictrict, Wuhan, Hubei Province, China

Close
Hubei Grand Everyday Bright Eyes Co., Ltd.

Hubei Grand Everyday Bright Eyes Co., Ltd.

Hubei Grand Everyday Bright Eyes Co., Ltd. was established in December 2003 and has been acquired by Grandpharma (China) Co., Ltd. in 2010.

Main products: Polyvinyl Alcohol Eye Dops (Ruizhu).

Official Website:www.ttmyy.com

Address:No.2, Checheng North Road, Zhuankou Economic and Technological Development Zone, Wuhan, Hubei Province, China

Close
Hubei Wellness Pharmaceutical Co., Ltd.

Hubei Wellness Pharmaceutical Co., Ltd.

Hubei Wellness Pharmaceutical Co., Ltd. was established in 2012 and has became a wholly-owned subsidiary of Grand Pharma (China) Co., Ltd. in December 2012.

Main products: Drugs: Lafutidine Dispersible Tablets, Nimesulide Capsules and Simvastatin Capsules, Erythromycin Enteric-coated Tablets, Loratadine Capsules, Telmisartan Hydrochlorothiazide Tablets; Healthcare products: Super-Bio L-Cysteine Capsules.

Official Website:No

Address: No.1, Sibao Road, Xiantao, Hubei Province, China

Close
Grand Pharmaceutical Huangshi Feiyun Co., Ltd.

Grand Pharmaceutical Huangshi Feiyun Co., Ltd.

Grand Pharmaceutical Huangshi Feiyun Co., Ltd. is a joint venture formed by Grandpharma (China) Co., Ltd. and Huangshi Feiyun Pharmaceutical Co., Ltd. in March 2013.

Main product: Antineoplastic Drugs, common traditional Chinese and Western medicine preparations. Representative products include Antineoplastic Hydroxycamptothecin for Injection, Hydroxycamptothecin Injection, Topotecan for Injection, Oxaliplatin for Injection and so on.

Official Website:www.hs-fy.com

Address:Economic and Technological Development Zone (No.69, East of Jinshan Avenue ) Huangshi City, Hubei Province, China

Close
Beijing Huajin Pharmaceutical Co., Ltd.

Beijing Huajin Pharmaceutical Co., Ltd.

Beijing Huajin Pharmaceutical Co., Ltd. was established in July 1992 and joined Grandpharma (China) Co., Ltd. in 2013.

Main products: Fructose Sodium Diphosphate Injection and Fructose Sodium Diphosphate Oral Solution.

Official Website:www.bjhuajin.com.cn

Address:Room 2901, C Block, Jin Chang’an Building, No.82, 4th Ring East Rd, Chaoyang District, Beijing, China

Close
Beijing Grand Jiuhe Pharmaceutical Co., Ltd.

Beijing Grand Jiuhe Pharmaceutical Co., Ltd.

Beijing Jiuhe Pharmaceutical Co., Ltd. was established in 1997 and joined Grandpharma (China) Co., Ltd in 2015.

Main product: Eucalyptol Limonene and Pinene Enteric Soft Capsules (Qienuo).

Official Website:www.bjjiuhe.com

Address:No.8, Jingbao Road, Doudian Town, Fangshan District, Beijing, China

Close
Xi’an Beilin Pharmaceutical Co., Ltd.

Xi’an Beilin Pharmaceutical Co., Ltd.

Xi'an Beilin Pharmaceutical Co., Ltd. was founded in 1969 and was restructured into a joint-stock company in 2001. In July 2016, the company became one of the member companies of Grandpharma (China) Co., Ltd.

Main products: Ophthalmic medications such as Fuming Tablets and Hexueming Tablets; laryngological medicines like Jinsang Sanjie Pills (capsules), Jinsangliyan Pills (capsules), Jinsangkaiyin Pills (capsules) and Jinsangqingyin Pills (capsules).

Official Website:www.beilinchina.cn

Address:西安市东关龙渠堡75号

Close
Wuhan Grandpharma Group Sales Co., Ltd.

Wuhan Grandpharma Group Sales Co., Ltd.

Wuhan Grandpharma Group Sales Co., Ltd. was established on November 30th, 2010, which is a wholly-owned subsidiary of Grandpharma (China) Co., Ltd.

Business scope: A professional sales company focusing on otolaryngologic and cardiovascular products with a marketing network covering the whole country. At present, it has a product group with core products such as Ruizhu, Baineiting Suspension and other otolaryngologic products, together with cardiovascular products like Xinweining, Nuofukang and so on.

Official Website:No

Address:23rd floor, A Block, Wuhan City Plaza, No.160, Qiaokou Road, Qiaokou District, Wuhan City, Hubei Province, China.

Close
Shanghai Xudong Haipu Pharmaceutical Co., Ltd.

Shanghai Xudong Haipu Pharmaceutical Co., Ltd.

Shanghai Xudong Haipu Pharmaceutical Co., Ltd. was founded in January 1993 and became a subsidiary company of Grandpharma (China) Co., Ltd. in 2018.

Main products: At present, the company mainly produces five major dosage forms with more than 90 varieties and more than 100 specifications, such as injections, tablets, capsules, suspensions and oral liquid preparations. It has 10 product subtypes including: anti-infective drugs, cardiovascular drugs, digestive system drugs, anti-tumor drugs, analgesics, contrast agents, anesthesia drugs, hormone drugs and central nervous system drugs.

Official Website:http://www.xdhelp.com/en/

Address:No. 879 Jinhu Road, Pudong New District, Shanghai.

Close

Medical Device

Tianjin Jingming New Technological Development Co., Ltd.

Tianjin Jingming New Technological Development Co., Ltd.

The company was founded in October 1995 and joined Grandpharma (China) Co., Ltd. in 2015.

Main products: Ophthalmic Hydroxypropyl Methylcellulose, Medical Sodium Hyaluronate Gel, Sodium Fluorescein Ophthalmic Test Paper, Tear Test Filter Strips, Tear Test Phenol Red Cotton Thread.

Official Website:www.tjjm.com.cn/

Address:K2-8-401, Haitai Green Industrial Base, Haitai Fazhan Sixth Road, Xiqing District, Tianjin, China

Close
Cardinovum GmbH (PRC JV)

Cardinovum GmbH (PRC JV)

Founded in October 9th, 2015, Cardinovum GmbH (PRC JV) is a high-end platform for interventional medical devices invested by Grandpharma (China) Co., Ltd.

Main product: DCB-Equipment.

Official Website:No

Address:23rd floor, A Block, Wuhan City Plaza, No. 160, Qiaokou Road, Qiaokou District, Wuhan, Hubei Province, China

Close

R&D

Wuhan Wuyao Technology Co., Ltd.

Wuhan Wuyao Technology Co., Ltd.

Wuhan Wuyao Technology Co., Ltd. was founded in June 2003. It is a profession pharmaceutical R&D institution invested by Grandpharma (China) Co., Ltd.

Official Website:No

Address:No.2, Checheng North Road, Zhuankou Economic and Technological Development Zone, Wuhan, Hubei Province, China

Close
top